New Developments in Biological Markers in Prostate Cancer

  • J. E. Pontes
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 118)

Abstract

The use of biological markers in the diagnosis and follow-up of patients with prostate cancer was pioneered by the work of Gutman et al. in 1936. In the intervening 50 years refinements in techniques and in the understanding of the physiological function of these normally occurring enzymes and proteins have enabled us to understand the potential and the problems associated with the use of these markers in clinical medicine. A review of biological markers in the prostate published previously by me (Pontes 1983) gave an extensive analysis of the value of specific and nonspecific markers in prostate cancer.

Keywords

Adenocarcinoma Perforation Phospho 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chan DW, Bruzek D, Rock R, Waldron C (1986) evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. Clin Chem 32: 1125Google Scholar
  2. Gutman E, Sproul E, Gutman A (1936) Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28: 485Google Scholar
  3. Liedtke RJ, Batjer JD (1984) Measurement of prostate-specific antigen by radioimmunoassay. Clin Chem 30: 649–652PubMedGoogle Scholar
  4. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Bruzek DJ, Rock RC, Brendler CB Walsh PC (1987) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766Google Scholar
  5. Pontes JE (1983) Bological markers in prostate cancer. J Urol 130: 1037PubMedGoogle Scholar
  6. Pontes JE, Jabalameli P, Montie J, Foemmel R, Howard PD; Boyett J (to be published), Disappearance rate of biological markers following radical prostatectomy —prognostic implications. Urology (to be published)Google Scholar
  7. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha F, Redwine E (1987) Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909PubMedCrossRefGoogle Scholar
  8. Vihko PM, Schroeder FH, Lukkarinen O, Vihko R (1982) Secretion into and elimination from blood circulation of prostate specific acid phosphatase, measured by radioimmunoassay. J Urol 128: 202PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin·Heidelberg 1990

Authors and Affiliations

  • J. E. Pontes
    • 1
  1. 1.Cleveland Clinic FoundationClevelandUSA

Personalised recommendations